Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Malaria Information and Prophylaxis, by Country [P]

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
CountryAreas with MalariaEstimated relative risk of Malaria for US Travelers2Drug Resistance3Malaria Species4Recommended Chemoprophlaxis5Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
PakistanAll areas (including all cities) at altitudes below 2,500 m (8,202 ft)ModerateChloroquineP. vivax 70%
P. falciparum 30%
Atovaquone-proguanil, doxycycline, or mefloquine
PalauNoneNoneNot ApplicableNot ApplicableNot Applicable
PanamaTransmission throughout the country. None in urban areas of Panama City or in the former Canal Zone.LowChloroquine (east of the Panama Canal)P. vivax 99%
P. falciparum 1%
Provinces east of the Panama Canal: Atovaquone-proguanil, doxycycline, mefloquine, or primaquine7

Other areas with malaria: Mosquito avoidance only
Papua New GuineaPresent throughout country at altitudes below 2,000 m (6,562 ft)HighChloroquine (both P. falciparum and P. vivax)P. falciparum 65-80%
P. vivax 10-30%
remainder P. malariae and P. ovale
Atovaquone-proguanil, doxycycline, or mefloquine
ParaguayPresent in the departments of Alto Paraná, Caaguazú, and CanendiyúVery LowNoneP. vivax 95%
P. falciparum 5%
Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or primaquine7
PeruAll departments below 2,000 m (6,562 ft) including cities of Iquitos and Puerto Maldonado. None in Lima province and coast south of Lima, and none in the cities of Ica and Nazca.

None in the highland tourist areas (Cuzco, Machu Picchu, and Lake Titicaca) and southern cities of Arequipa, Moquegua, Puno, and Tacna.
LowChloroquineP. vivax 85%
P. falciparum 15%
Atovaquone-proguanil, doxycycline, or mefloquine
PhilippinesPresent in rural areas below 600 m (1,969 ft) on islands of Basilan, Luzon, Mindanao, Mindoro, Palawan, Sulu (Jolo), and Tawi-Tawi. None in urban areas.LowChloroquineP. falciparum 70-80%
P. vivax 20-30%
Atovaquone-proguanil, doxycycline, or mefloquine
Pitcairn Islands (U.K.)NoneNoneNot ApplicableNot ApplicableNot Applicable
PolandNoneNoneNot ApplicableNot ApplicableNot Applicable
PortugalNoneNoneNot ApplicableNot ApplicableNot Applicable
Puerto Rico (U.S.)NoneNoneNot ApplicableNot ApplicableNot Applicable
  1. The information presented herein was accurate at the time of publication; however, factors that can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection, can markedly affect local malaria transmission patterns.
  2. This estimate of risk is based on numbers of cases of malaria reported in US travelers and the estimated volume of travel to these countries. In some instances the risk may be low because the actual intensity of transmission is low in that country. In other instances, significant malaria transmission may occur only in small focal areas of the country where US travelers seldom go. Thus even though the risk for the average traveler to that country may be low, the risk for the rare traveler going to the areas with higher transmission intensity will of course be higher. For some countries that are rarely visited by US travelers, there is insufficient information to make a risk estimate.
  3. Refers to P. falciparum malaria unless otherwise noted.
  4. Estimates of malaria species are based on best available data from multiple sources.
  5. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
  6. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
  7. Primaquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine. The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO